Invion Ltd (IVX)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013248)
◆英語タイトル:Invion Ltd (IVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013248
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:36
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Invion Ltd (Invion) is a life sciences company that develops products for the treatment of inflammatory diseases such as chronic inflammatory, airway disease and inflammation caused by autoimmune disease. The company’s pipeline products include INV102 nadolol, a beta blocker for inflammatory lung conditions; INV103 ala-Cpn10, a naturally occuring human protein for the treatment of chronic inflammation; and INV104 zafirlukast, a leukotriene receptor antagonist for the prevention of asthma attacks. Invion also conducts clinical development programs for developing zafirlukast as a novel non-steroidal, anti-inflammatory treatment for asthma. The company has operations in Australia and the US. Invion is headquartered in Brisbane, Queensland, Australia.

Invion Ltd (IVX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Invion Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Invion Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Invion Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Invion Enters into Development and Licensing Agreement with Hovione 10
Invion Enters Into Co-Development Agreement With 3M Drug Delivery Systems For INV102 And INV104 11
Licensing Agreements 12
Invion Enters Into Licensing Agreement With Accolade For Zafirlukast 12
Equity Offering 14
Invion Raises USD0.5 Million in Private Placement of Ordinary Shares 14
Invion Raises USD0.4 Million in Private Placement of Shares 15
Invion to Raise USD15 Million in Private Placement of Shares 16
Invion Completes Rights Offering Of Shares For USD0.8 Million 17
Invion Completes Private Placement Of Shares For US$4.5 Million 19
Invion Completes Private Placement Of Shares For US$1.9 Million 20
Invion Completes Rights Offering Of Shares For US$1 Million 21
CBio Completes Private Placement Of Common Stock For US$1.8 Million 23
CBio Completes Private Placement Of Shares For US$2.4 Million 24
CBio Completes Rights Issue Of US$11.4 Million 25
CBio Completes Non-Renounceable Rights Issue Of Common Stock For US$6 Million 27
CBio Completes Private Placement Of US$4.93 Million 28
Debt Offering 29
CBio Completes Private Placement Of Convertible Notes For US$0.16 Million 29
Acquisition 30
CBio Completes Acquisition Of Inverseon, Clinical-Stage Pharma Company 30
Invion Ltd – Key Competitors 32
Invion Ltd – Key Employees 33
Invion Ltd – Locations And Subsidiaries 34
Head Office 34
Recent Developments 35
Financial Announcements 35
Jul 29, 2016: Appendix 4C – cashflow statement for the June 2016 quarter 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Invion Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Invion Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Invion Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Invion Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Invion Enters into Development and Licensing Agreement with Hovione 10
Invion Enters Into Co-Development Agreement With 3M Drug Delivery Systems For INV102 And INV104 11
Invion Enters Into Licensing Agreement With Accolade For Zafirlukast 12
Invion Raises USD0.5 Million in Private Placement of Ordinary Shares 14
Invion Raises USD0.4 Million in Private Placement of Shares 15
Invion to Raise USD15 Million in Private Placement of Shares 16
Invion Completes Rights Offering Of Shares For USD0.8 Million 17
Invion Completes Private Placement Of Shares For US$4.5 Million 19
Invion Completes Private Placement Of Shares For US$1.9 Million 20
Invion Completes Rights Offering Of Shares For US$1 Million 21
CBio Completes Private Placement Of Common Stock For US$1.8 Million 23
CBio Completes Private Placement Of Shares For US$2.4 Million 24
CBio Completes Rights Issue Of US$11.4 Million 25
CBio Completes Non-Renounceable Rights Issue Of Common Stock For US$6 Million 27
CBio Completes Private Placement Of US$4.93 Million 28
CBio Completes Private Placement Of Convertible Notes For US$0.16 Million 29
CBio Completes Acquisition Of Inverseon, Clinical-Stage Pharma Company 30
Invion Ltd, Key Competitors 32
Invion Ltd, Key Employees 33

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Invion Ltd (IVX)-製薬・医療分野:企業M&A・提携分析(Invion Ltd (IVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆